Eriksen EF. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev. 1986;7(4):379–408. https://doi.org/10.1210/edrv-7-4-379.

Article  PubMed  CAS  Google Scholar 

Andreasen CM, El-Masri BM, MacDonald B, et al. Local coordination between intracortical bone remodeling and vascular development in human juvenile bone. Bone. 2023;173:116787. https://doi.org/10.1016/j.bone.2023.116787.

Article  PubMed  Google Scholar 

Kobayashi Y, Uehara S, Udagawa N, et al. Regulation of bone metabolism by Wnt signals. J Biochem. 2016;159(4):387–92. https://doi.org/10.1093/jb/mvv124.

Article  PubMed  CAS  Google Scholar 

Søe K, Andersen TL, Hinge M, et al. Coordination of fusion and trafficking of pre-osteoclasts at the marrow–bone interface. Calcif Tissue Int. 2019;105(4):430–45. https://doi.org/10.1007/s00223-019-00575-4.

Article  PubMed  CAS  Google Scholar 

Huang D, Zhao C, Li R, et al. Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis. Nat Commun. 2022;13(1):5338. https://doi.org/10.1038/s41467-022-33006-4.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fu Q, Bustamante-Gomez NC, Reyes-Pardo H, et al. Reduced osteoprotegerin expression by osteocytes May contribute to rebound resorption after denosumab discontinuation. JCI Insight. 2023;8(18):e167790. https://doi.org/10.1172/jci.insight.167790.

Article  PubMed  PubMed Central  Google Scholar 

Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–9.

Article  PubMed  CAS  Google Scholar 

Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972–80. https://doi.org/10.1210/jc.2010-1502.

Article  PubMed  CAS  Google Scholar 

Uday S, Gaston CL, Rogers L, et al. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone. J Clin Endocrinol Metab. 2018;103:596–603. https://doi.org/10.1210/jc.2017-02025.

Article  PubMed  Google Scholar 

Kim AS, Girgis CM, McDonald MM. Osteoclast recycling and the rebound phenomenon following denosumab discontinuation. Curr Osteoporos Rep. 2022;20(6):505–15. https://doi.org/10.1007/s11914-022-00756-5.

Article  PubMed  PubMed Central  Google Scholar 

McClung MR, Wagman RB, Miller PD, et al. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017;28(5):1723–32.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yukishima T, Ebina K, Etani Y, et al. Impact of switching from bisphosphonates to denosumab, teriparatide, or Romosozumab in patients with postmenopausal osteoporosis: a case-control study. Osteoporos Int. 2025;36(3):531–8. https://doi.org/10.1007/s00198-025-07386-4.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kim AS, Taylor VE, Castro-Martinez A, et al. Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition. J Bone Miner Res. 2024;39(4):484–97. https://doi.org/10.1093/jbmr/zjae023.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schumaier A, Grawe B. Proximal humerus fractures: evaluation and management in the elderly patient. Geriatr Orthop Surg Rehabil. 2018;9:2151458517750516. https://doi.org/10.1177/2151458517750516.

Article  PubMed  PubMed Central  Google Scholar 

Amin U, McPartland A, O’Sullivan M, et al. An overview of the management of osteoporosis in the aging female population. Womens Health. 2023;19:17455057231176656. https://doi.org/10.1177/17455057231176655.

Article  CAS  Google Scholar 

LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2243. https://doi.org/10.1007/s00198-022-06479-8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Anish RJ, Nair A. Osteoporosis management-current and future perspectives–a systemic review. J Orthop. 2024;53:101–13. https://doi.org/10.1016/j.jor.2024.03.002.

Article  PubMed  PubMed Central  Google Scholar 

Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo‐controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2005;20(12):2274–82. https://doi.org/10.1359/jbmr.2005.20.12.2274.

Article  Google Scholar 

Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564–71. https://doi.org/10.1200/JCO.2008.19.2146.

Article  PubMed  CAS  Google Scholar 

Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J ClinOncol. 2007;25(28):4431–7. https://doi.org/10.1200/JCO.2007.11.86.

Article  CAS  Google Scholar 

Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009;24(2):182–95. https://doi.org/10.1359/jbmr.081112.

Article  PubMed  CAS  Google Scholar 

Miller PD, Pannacciulli N, Malouf-Sierra J, et al. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int. 2020;31:181–91. https://doi.org/10.1007/s00198-019-05233-x.

Article  PubMed  CAS  Google Scholar 

Narayanan P. Denosumab: a comprehensive review. South Asian J Cancer. 2013;2(4):272–7. https://doi.org/10.4103/2278-330X.119895.

Article  PubMed  PubMed Central  Google Scholar 

Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis— 2020 Update Executive Summary. Endocr Pract. 2020;26(5):564–70. https://doi.org/10.4158/GL-2020-0524.

Article  PubMed  Google Scholar 

Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44. https://doi.org/10.1007/s00198-018-4704-5.

Article  PubMed  CAS  Google Scholar 

Lyu H, Zhao SS, Yoshida K, et al. Delayed Denosumab Injections and Bone Mineral Density Response: an electronic health record-based study. J Clin Endocrinol Metab. 2020;105(5):1435–44. https://doi.org/10.1210/clinem/dgz321.

Article  PubMed  PubMed Central  Google Scholar 

Burckhardt P, Faouzi M, Buclin T, The Swiss Denosumab Study Group, et al. Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res. 2021;36(9):1717–28. https://doi.org/10.1002/jbmr.4335.

Freemantle N, Satram-Hoang S, Tang ET, DAPS Investigators, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317–26. https://doi.org/10.1007/s00198-011-1780-1.

Ferrari S, Langdahl B. Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol. 2023;19(5):307–17. https://doi.org/10.1038/s41584-023-00935-3.

Article  PubMed  CAS  Google Scholar 

Sasaki F, Hayashi M, Ono T, et al. The regulation of RANKL by mechanical force. J Bone Miner Metab. 2021;39:34–44. https://doi.org/10.1007/s00774-020-01145-7.

Article